Role of ustekinumab in treatment of ulcerative colitis: a narrative review

被引:1
作者
Grova, Mauro [1 ]
Vitello, Alessandro [2 ]
Mannino, Mariella [3 ]
Casa, Angelo [3 ]
Renna, Sara [3 ]
Macaluso, Fabio Salvatore [3 ]
Orlando, Ambrogio [3 ]
机构
[1] Villa Sofia Cervello Hosp, Dept Med, Digest Endoscopy Unit, I-90100 Palermo, Italy
[2] S Elia Raimondi Hosp, Gastroenterol & Endoscopy Unit, i-93100 Caltanissetta, Italy
[3] Villa Sofia Cervello Hosp, Dept Med, Inflammat Bowel Dis Unit, Palermo, Italy
关键词
biologic therapy; inflammatory bowel disease; IL-12; IL-23; positioning; ulcerative colitis; ustekinumab; INFLAMMATORY-BOWEL-DISEASE; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; ACTIVE PSORIATIC-ARTHRITIS; DOUBLE-BLIND; MAINTENANCE THERAPY; CYTOKINE; EFFICACY; SAFETY; RECEPTOR; IL-23;
D O I
10.2217/imt-2023-0106
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The therapeutic armamentarium for gastroenterologists in treating ulcerative colitis (UC) has been rapidly growing since the introduction of monoclonal antibodies directed against anti-TNFs. Ustekinumab is a monoclonal antibody binding the shared p40 subunit of IL-12 and IL-23, and the inhibition of these two cytokines, implicated in host response to microbial pathogens, has demonstrated clinical efficacy in different immune-mediated diseases, including moderate-to-severe UC. This narrative review summarizes the newest clinical evidence regarding the efficacy, effectiveness and safety of ustekinumab in moderate-to-severe UC, including specific situations (pregnancy, breastfeeding, elderly/pediatric populations, extraintestinal manifestations, acute severe UC, pouchitis and dual biological therapy). Finally, positioning is discussed in light of the existing evidence. Ustekinumab (UST) is a biological drug that has been recently licensed as a novel therapy for ulcerative colitis, one of the two main conditions that constitute inflammatory bowel diseases. UST has been previously successfully used in psoriasis and psoriatic arthritis, two conditions in which dysregulation of the immune system causes inflammation in the skin and joints, and Crohn's disease, a type of inflammatory bowel disease. This led to great interest in the use of UST for treating patients with moderate and severe ulcerative colitis. UST is administered with a weight-based intravenous infusion followed by subcutaneous administration every 8 weeks, which can be performed at home and is effective in reducing symptoms of the disease with a particularly favorable safety profile. These features make UST a suitable option for treating especially elderly and frail patients, as well as patients who did not benefit or had side effects with other biological therapies and patients who also suffer from psoriasis or psoriatic arthritis. This narrative review summarizes the newest clinical evidence of the efficacy, effectiveness and safety of ustekinumab in moderate-to-severe ulcerative colitis, including specific situations and the consequent positioning of this drug.
引用
收藏
页码:1539 / 1552
页数:14
相关论文
共 99 条
[1]   Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis [J].
Abraham, Bincy P. ;
Ott, Elyssa ;
Busse, Christopher ;
Murphy, Conor ;
Miller, Lindsay ;
Baumgart, Daniel C. ;
Scherl, Ellen ;
Gasink, Christopher .
CROHNS & COLITIS 360, 2022, 4 (03)
[2]   Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension [J].
Abreu, Maria T. ;
Rowbotham, David S. ;
Danese, Silvio ;
Sandborn, William J. ;
Miao, Ye ;
Zhang, Hongyan ;
Tikhonov, Ilia ;
Panaccione, Remo ;
Hisamatsu, Tadakazu ;
Scherl, Ellen J. ;
Leong, Rupert W. ;
Arasaradnam, Ramesh P. ;
Afif, Waqqas ;
Peyrin-Biroulet, Laurent ;
Sands, Bruce E. ;
Marano, Colleen .
JOURNAL OF CROHNS & COLITIS, 2022, 16 (08) :1222-1234
[3]   Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis [J].
Adedokun, Omoniyi J. ;
Xu, Zhenhua ;
Marano, Colleen ;
O'Brien, Chris ;
Szapary, Philippe ;
Zhang, Hongyan ;
Johanns, Jewel ;
Leong, Rupert W. ;
Hisamatsu, Tadakazu ;
Van Assche, Gert ;
Danese, Silvio ;
Abreu, Maria T. ;
Sands, Bruce E. ;
Sandborn, William J. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (10) :2244-+
[4]   Accelerated ustekinumab dosing as rescue therapy in acute severe ulcerative colitis [J].
Affendi, Nik Arsyad Nik Muhamad ;
Ooi, Choon Jin ;
Hilmi, Ida Normiha .
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2022, 31 (04) :478-480
[5]   Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease [J].
Alayo, Quazim A. ;
Fenster, Marc ;
Altayar, Osama ;
Glassner, Kerri L. ;
Llano, Ernesto ;
Clark-Snustad, Kindra ;
Patel, Anish ;
Kwapisz, Lukasz ;
Yarur, Andres J. ;
Cohen, Benjamin L. ;
Ciorba, Matthew A. ;
Thomas, Deborah ;
Lee, Scott D. ;
Loftus, Edward V., Jr. ;
Fudman, David, I ;
Abraham, Bincy P. ;
Colombel, Jean-Frederic ;
Deepak, Parakkal .
CROHNS & COLITIS 360, 2022, 4 (01)
[6]   Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis [J].
Alsoud, Dahham ;
De Hertogh, Gert ;
Compernolle, Griet ;
Tops, Sophie ;
Sabino, Joao ;
Ferrante, Marc ;
Thomas, Debby ;
Vermeire, Severine ;
Verstockt, Bram .
JOURNAL OF CROHNS & COLITIS, 2022, 16 (10) :1562-1570
[7]   Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study [J].
Amiot, Aurelien ;
Filippi, Jerome ;
Abitbol, Vered ;
Cadiot, Guillaume ;
Laharie, David ;
Serrero, Melanie ;
Altwegg, Romain ;
Bouhnik, Yoram ;
Peyrin-Biroulet, Laurent ;
Gilletta, Cyrielle ;
Roblin, Xavier ;
de Chambrun, Guillaume Pineton ;
Vuitton, Lucine ;
Bourrier, Anne ;
Nancey, Stephane ;
Gornet, Jean-Marc ;
Nahon, Stephane ;
Bouguen, Guillaume ;
Viennot, Stephanie ;
Pariente, Benjamin ;
Fumery, Mathurin .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (11) :1039-1046
[8]   Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study [J].
Asscher, Vera E. R. ;
Biemans, Vince B. C. ;
Pierik, Marieke J. ;
Dijkstra, Gerard ;
Lowenberg, Mark ;
van der Marel, Sander ;
de Boer, Nanne K. H. ;
Bodelier, Alexander G. L. ;
Jansen, Jeroen M. ;
West, Rachel L. ;
Haans, Jeoffrey J. L. ;
van Dop, Willemijn A. ;
Weersma, Rinse K. ;
Hoentjen, Frank ;
Maljaars, P. W. Jeroen .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (08) :1366-1376
[9]   Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study [J].
Avni-Biron, Irit ;
Mishael, Tali ;
Zittan, Eran ;
Livne-Margolin, Moran ;
Zinger, Adar ;
Tzadok, Roi ;
Goldenberg, Rosie ;
Kopylov, Uri ;
Ron, Yulia ;
Hadar, Eran ;
Helman, Sarit ;
Granovsky, Sorina Grisaru ;
Ollech, Jacob E. ;
Arazi, Ayelet ;
Farkash, Rivka ;
Pauker, Maor H. ;
Yanai, Henit ;
Dotan, Iris ;
Shitrit, Ariella Bar-Gil .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (09) :1361-1369
[10]   INTERLEUKIN-12 (IL-12) INDUCES TYROSINE PHOSPHORYLATION OF JAK2 AND TYK2 - DIFFERENTIAL USE OF JANUS FAMILY TYROSINE KINASES BY IL-2 AND IL-12 [J].
BACON, CM ;
MCVICAR, DW ;
ORTALDO, JR ;
REES, RC ;
O'SHEA, JJ ;
JOHNSTON, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (01) :399-404